Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| calcium channel blockers, nifedipine derivatives | 837 | 120054-86-6 |
None
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 8.40 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 9.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 22 hours | Lombardo F, Berellini G, Obach RS |
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 4.684 | Moderate | 0.66 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.399 | Moderate | 0.66 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 3.112 | 10^-6 cm/s | Moderate | 0.66 |
| dh-clint | Dog hepatocyte intrinsic clearance | 60.814 | uL/min/10^6 cells | Moderate | 0.66 |
| dppb | Dog plasma protein binding (% unbound) | 0.160 | % | Moderate | 0.66 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 0.680 | % | Moderate | 0.66 |
| herg | hERG pIC50 | 6.229 | pIC50 | Moderate | 0.66 |
| hh-clint | Human hepatocyte intrinsic clearance | 46.666 | uL/min/10^6 cells | Moderate | 0.66 |
| hlm-clint | Human liver microsomal intrinsic clearance | 254.683 | uL/min/mg protein | Moderate | 0.66 |
| hppb | Human plasma protein binding (% unbound) | 0.240 | % | Moderate | 0.66 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ZAP70 | 49 | |||
| kinase-selectivity-class | AXL,BRAF,GRK2,PDK4,PIK3CD,STK33,TEK | 7 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 6.457 | Moderate | 0.66 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 190.985 | Moderate | 0.66 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.220 | Moderate | 0.66 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 19.679 | Moderate | 0.66 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 0.470 | % | Moderate | 0.66 |
| rh-clint | Rat hepatocyte intrinsic clearance | 202.768 | uL/min/10^6 cells | Moderate | 0.66 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 1.350 | % | Moderate | 0.66 |
| rppb | Rat plasma protein binding (% unbound) | 0.210 | % | Moderate | 0.66 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 0.634 | uM | Moderate | 0.66 |
None
None
None
None
None
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D002121 | Calcium Channel Blockers |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D049990 | Membrane Transport Modulators |
None
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.38 | Basic |
| pKa2 | 2.37 | Basic |
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Voltage-gated L-type calcium channel | Ion channel | BLOCKER | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
| Translocator protein | Transporter | Ki | 6.02 | CHEMBL | |||||
| D(1A) dopamine receptor | GPCR | Ki | 6.43 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | Ki | 6.55 | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 6.05 | CHEMBL | |||||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.49 | CHEMBL | |||||
| Multidrug resistance protein 1 | Transporter | Ki | 7.43 | WOMBAT-PK | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 6.06 | CHEMBL | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 6.07 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.27 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.73 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.06 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 7 | GPCR | Ki | 6.50 | CHEMBL | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 10 | CHEMBL | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 6.18 | CHEMBL | |||||
| D(3) dopamine receptor | GPCR | Ki | 6.37 | CHEMBL | |||||
| D(1B) dopamine receptor | GPCR | Ki | 5.91 | CHEMBL | |||||
| Histamine H1 receptor | GPCR | Ki | 7.05 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 5.67 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 6.14 | CHEMBL | |||||
| Mu-type opioid receptor | GPCR | Ki | 6.89 | CHEMBL | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 6.35 | CHEMBL | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 6.23 | CHEMBL | |||||
| Adenosine receptor A3 | GPCR | Ki | 5.72 | CHEMBL | |||||
| Alpha-1D adrenergic receptor | GPCR | Ki | 6.77 | CHEMBL | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 7.25 | CHEMBL | |||||
| Kappa-type opioid receptor | GPCR | Ki | 6.46 | CHEMBL | |||||
| Delta-type opioid receptor | GPCR | Ki | 6.40 | CHEMBL | |||||
| Voltage-dependent T-type calcium channel subunit alpha-1H | Ion channel | Ki | 5.82 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 5A | GPCR | Ki | 6.37 | CHEMBL | |||||
| Histamine H3 receptor | GPCR | Ki | 5.67 | CHEMBL | |||||
| Transmembrane protein 97 | Enzyme | Ki | 6.49 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 6.44 | CHEMBL | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 6.42 | CHEMBL | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 8.20 | CHEMBL | |||||
| Alpha-1D adrenergic receptor | GPCR | Ki | 7.08 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | Ki | 6.53 | CHEMBL | |||||
| Adenosine receptor A1 | GPCR | Ki | 4.38 | CHEMBL | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 9.42 | CHEMBL | |||||
| Voltage-gated L-type calcium channel | Ion channel | Ki | 7.22 | CHEMBL |
| ID | Source |
|---|---|
| 113145-69-0 | SECONDARY_CAS_RN |
| C0208704 | UMLSCUI |
| CHEBI:7572 | CHEBI |
| CHEMBL2051956 | ChEMBL_ID |
| CHEMBL405355 | ChEMBL_ID |
| DB14068 | DRUGBANK_ID |
| C054074 | MESH_SUPPLEMENTAL_RECORD_UI |
| 463 | IUPHAR_LIGAND_ID |
| 6938 | INN_ID |
| N9DG6ZTC43 | UNII |
| 6918097 | PUBCHEM_CID |
| N9DG6ZTC43 | INXIGHT DRUGS |
None